

AF/1648
ZFC ✓

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON

20 AUGUST 2004



Arthur E. Connor
NAME OF PERSON MAILING THE DOCUMENT

20 August 04
DATE

Attorney Docket No. B45158

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nathalie Garcon

Serial No.: 09/807,657

Group Art Unit No.: 1648

Filed: 16 April 2001

Examiner: Z. Lucas

For: ADJUVANT SYSTEMS AND VACCINES

Commissioner for Patents
Alexandria, VA

AMENDMENT & RESPONSE UNDER 37 C.F.R. §1.116

This amendment and response is to the Office Action mailed April 20, 2004 (herein "Office Action"). The time for responding is extended one month from 20 July 2004 to 20 August 2004, by the enclosed Petition for Extension of Time and the charge of fees for a one-month extension required by this paper to Deposit Account No 19-2570. Authorization is granted to charge any necessary fees to or otherwise required for this application during its pendency to Deposit Account No. 19-2570.

Amendments to the specification begin on page 2 of this paper

Amendments to the claims begin on page 3 of this paper.

Remarks begin on page 19 of this paper.

Serial No.: 09/807,657
Group Art Unit No.: 1648

Please amended the paragraph beginning at page 12, line 29 through page 13, line 13 as follows:

The formulations may also contain an anti-tumour antigen and be useful for the immunotherapeutic treatment of cancers. For example, the adjuvant formulation finds utility with tumour rejection antigens such as those for prostate, breast, colorectal, lung, pancreatic, renal or melanoma cancers. Exemplary antigens include MAGE 1 and MAGE 3 or other MAGE antigens for the treatment of melanoma, PRAME, BAGE, or GAGE (Robbins and Kawakami, 1996, Current Opinions in Immunology 8, pps 628-636; Van den Eynde et al., International Journal of Clinical & Laboratory Research (submitted 1997); Correale et al. (1997), Journal of National Cancer Institute 89, p293. Indeed these antigens are expressed in a wide range of tumour types such as melanoma, lung carcinoma, sarcoma and bladder carcinoma. Other Tumor-Specific antigens are suitable for use with adjuvant of the present invention and include, but are not restricted to Prostate specific antigen (SPA) or Her-2/neu, KSA (GA733) MUC-1 and carcinoembryonic antigen (CEA). Other antigens have been put forward as being pan-cancer therapeutic antigens including luteinizing hormone-releasing hormone (gonadotropin-releasing hormone) ("LHRH(GnRH))-(LHRH(GnRH))₂, Tyrosinase and Survivin. Accordingly in one aspect of the present invention there is provided a vaccine comprising an adjuvant composition according to the invention and a tumour rejection antigen.